Advertisement

Inpharma Weekly

, Volume 1138, Issue 1, pp 15–16 | Cite as

Zolmitriptan zaps migraine in ‘real-life’ setting

  • Larry Prescott
Newsletter Article

Abstract

Zolmitriptan, a novel serotonin (5-HT) 1B/1D receptor antagonist developed for the acute treatment of migraine, is proving to have consistent efficacy across a range of migraine types. Zolmitriptan was developed to improve on the low bioavailability of sumatriptan. Sumatriptan was the first triptan to become available for patients with migraine and is considered to be the gold standard treatment. Preclinical studies with zolmitriptan indicate that the agent has a novel dual mechanism of action, having effects at both central (trigeminal nucleus caudalis) and peripheral (trigeminovascular system) targets. A number of new clinical studies demonstrating the value of this antimigraine agent were presented at the 50th Annual Meeting of the American Academy of Neurology [ Minneapolis, US; May 1998 ].

Keywords

Migraine Fluoxetine Sumatriptan Migraine Attack Zolmitriptan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1998

Authors and Affiliations

  • Larry Prescott

There are no affiliations available

Personalised recommendations